Home Exclusive: Capital Backs Commercial Progress of China's First Homegrown Phaco-Vitrectomy System as Rhino Health Closes New Round

Exclusive: Capital Backs Commercial Progress of China's First Homegrown Phaco-Vitrectomy System as Rhino Health Closes New Round

Nov 05, 2026 08:00 CST Updated 08:00
Rhino Health

Developer of High-End Ophthalmic Surgical Equipment

HANYU CAPITAL

Healthcare and Technology Investment Bank

In capital

Healthcare Investment Firm

VCBeat has learned exclusively that Rhino Health, a developer of high-end ophthalmic surgical equipment, recently closed a B+ round of nearly RMB 100 million. The round was led by In Capital, with Zhuhai Technology Industry Group participating, and Hanyu Capital serving as the exclusive financial advisor. The proceeds will be mainly used for the registration of Rhino Health's innovative ophthalmic products, the overseas expansion of existing products and domestic commercialization.


This is the second round Rhino Health has completed this year. At the end of March, Guangzhou Yuexiu Industrial Investment Fund Management Co., Ltd. (Yuexiu Industrial Fund) and Taiyu Capital invested nearly RMB 100 million in the company's B round. In both the B and B+ rounds, the lead investors were market-oriented first-tier investment institutions. If B-round investors focused more on product approval and launch, B+ investors are more focused on the commercialization of Rhino Health's approved products.


"Investors today are watching a company's ability to commercialize. This round is essentially the capital market's recognition of Rhino Health's ability to turn products into revenue," Zhang Chi, founder of Rhino Health, said bluntly in an interview with VCBeat.


From Critical Clinical Needs in Ophthalmology to Building a Portfolio of High-End Ophthalmic Devices


In the current market, China has nearly 200 million cataract patients and 46 million patients with fundus diseases. The two conditions often occur together and require combined surgery. As the core procedures for cataract and fundus diseases, phacoemulsification and vitrectomy account for about 50% of all ophthalmic surgeries.


Compared with traditional separate devices, a combined phaco-vitrectomy system can complete combined anterior and posterior segment treatment in a single surgery, reducing the number of procedures and trauma. But for a long time this market has been dominated by overseas brands such as Alcon and Bausch + Lomb. Equipment procurement costs are high and maintenance cycles long, patient treatment costs remain elevated, and quality ophthalmic resources struggle to reach primary care.


This situation is changing as domestic devices reach the market. On December 15, 2025, the National Medical Products Administration approved Rhino Health's self-developed Genesis I & II combined phaco-vitrectomy system for market launch (NMPA Registration No. 20253162583). It is also the first product of its kind approved in China.



Genesis Series


The core specifications of the Genesis Series are benchmarked directly against the latest imported models: vitrectomy cutting rates of 7,500cpm and 10,000cpm, up to 20,000cpm in bidirectional mode, supporting 20G to 27G vitrectomy procedures; phacoemulsification uses the world's lowest 28.5kHz frequency and the smallest 1.8mm incision to reduce postoperative iatrogenic astigmatism and incision thermal damage; a dual-pump system with 660mmHg intelligent fluid control enables real-time intraocular pressure monitoring; dual LED light sources with wavelength adjustment technology provide surgeons with a clear field of view; and a dual-linear wireless Bluetooth footswitch offers more flexible operation.


Beyond the Genesis Series, Rhino Health's product matrix is extending further to address urgent clinical needs in ophthalmology:


On the device side, the Romulus product, positioned as a "full-process solution for anterior and posterior segment ophthalmic surgery," made its official public debut at CCOS 2026. According to Zhang Chi, the product has been accepted by the National Medical Products Administration and is expected to be approved and launched between the end of this year and early next year. Unlike the Genesis Series, Romulus adopted a platform architecture from the outset, and Rhino Health's innovative technologies, such as intraoperative OCT imaging and laser vitrectomy, will later be integrated into the platform. Rhino Health's fiber-optic OCT has completed animal studies, which would be the world's first attempt to integrate imaging observation with a combined phaco-vitrectomy system.



Romulus


On the consumables side, the disposable phaco packs and vitrectomy packs that come with the Genesis Series have scaled up alongside device sales. Rhino Health's consumables compatible with imported devices have also entered some tertiary hospitals and the vast majority of secondary hospitals. Rhino Health hopes to further lower costs for clinical institutions through localized consumables.


It is worth stressing that what Rhino Health aims to build is not a single piece of hardware, but a full-chain solution of "equipment + consumables + training" that starts from clinical needs.


Commercialization Outpaces the Founder's Expectations


"Both the number of installations and the number of signed contracts far exceeded my expectations," Zhang Chi said.

According to the company, the Genesis Series began commercialization in June this year, and in less than five months Rhino Health had signed contracts for more than 30 units and completed more than 10 installations. Zhang Chi expects the full-year signed volume to approach 60 units. Under its original plan, it aimed to reach average annual sales of 100 units within two to three years of launch. Signed sales are advancing in both public and private hospitals.


Behind these signings lie not only the advantages of Rhino Health's devices but also growing recognition from clinical teams.

For example, in June this year, the team of Director Tao Liming at the Second Affiliated Hospital of Anhui Medical University completed a clinical trial of Genesis, commenting that it has a "mature overall design, operating logic that fits clinical habits, excellent intraoperative fluid management and outstanding operational stability"; the team of Director Yu Tongli at Jinan First People's Hospital used Genesis to complete four cataract surgeries, with all patients reaching postoperative visual acuity above 0.8 and some recovering to 1.0. Director Yu Tongli believes the device "has delivered satisfactory answers on anterior chamber stability, surgical efficiency and safety, and more importantly, clear advantages in consumable costs and maintenance response." Zhang Chi said more significant real-world study data will be released soon.



The Rhino Health team at a clinical site


The recognition from clinical teams is tied to some of Rhino Health's initiatives:


On one hand, Rhino Health participates intensively in ophthalmic academic conferences and public welfare activities, offering clinicians product demonstrations and hands-on experience. In April this year, for example, it joined forces with Shandong Provincial Hospital to carry out charitable cataract surgeries in Aba at an altitude of more than 3,000 meters, completing more than 100 procedures in total, and the Genesis Series became the first domestic combined phaco-vitrectomy system to reach an altitude above 3,000 meters; in June, during academic conferences held in Shanghai, Leshan and Kunming, the entire Rhino Health team traveled to the three cities to support on-site device operations simultaneously; in September, at CCOS 2026, the national ophthalmology academic congress, Genesis and Romulus appeared on the same stage... From plateaus to coastal areas, from primary care to tertiary hospitals, Rhino Health is building direct evidence of product reliability through repeated validation in different scenarios.


On the other hand, Rhino Health keeps advancing its training system. This is related to Zhang Chi's personal experience: he himself came from a primary-care hospital, and "making good devices affordable for primary-care doctors and helping them quickly master advanced surgical skills" was one of his original motivations for founding Rhino Health.




Rhino Health has trained more than 200 ophthalmologists to date, using Wetlab (live practice on pig or rabbit eyes) and Drylab (simulated eyes) formats to provide differentiated training for doctors at different levels. As the first cohort completes training, they will further reach their own hospitals and surrounding areas, raising local doctors' skill levels. Although the industry usually ties training to commercial promotion, Zhang Chi says that "solving the pain points of primary care has nothing to do with utility." Objectively, however, training undoubtedly shortens doctors' learning curve, makes them "know how to use the device and dare to use it," and paves the way for Rhino Health's commercialization.


While validating in the domestic market, Rhino Health has also started laying out overseas markets.

At APVRS 2026, held in Gold Coast, Australia, in August this year, for example, Professor Zhao Mingwei of Peking University People's Hospital presented China's progress in fundus surgical equipment in the "World Retina Spotlight" session, and Genesis was featured in the presentation. As China's first combined phaco-vitrectomy system, Genesis is steadily attracting overseas attention.


At the same time, Rhino Health is accelerating overseas registration. Its CE and FDA registration testing has been completed. In Russia, annual sales are expected to reach 10-15 units; registration and partnerships are also progressing in the Middle East, ASEAN and other regions. Zhang Chi said overseas sales are expected to reach 50 units overall in 2027.


"Truly going overseas also means confronting different countries' and regions' regulatory systems, clinical habits, channel networks, after-sales service and brand building." Zhang Chi is clear that this path will not be easier than at home. "But our ophthalmic devices have already begun to go global."


After Financing


With the funding in place, Zhang Chi said the focus will be on the following directions:


First, strengthening device integration, further exploring the fusion of intraoperative imaging capabilities such as OCT with surgical devices; second, improving intelligence, working with third-party partners on parameter settings, process assistance and automated control; third, accelerating globalization, further advancing overseas registration, clinical collaboration and market expansion.


The team is key to supporting Rhino Health's longer journey. Zhang Chi has a clinical background and more than a decade of experience in ophthalmic device market registration and training at foreign companies; core team members come from international giants such as Alcon, Bausch + Lomb and GE HealthCare. The seasoned technical team has also secured multiple certifications for the company, which now holds more than 10 invention patents, more than 10 utility models and more than 10 years of technology reserves, with freedom-to-operate (FTO) analysis showing very low infringement risk.


This also gives Rhino Health more confidence. For the company, from the approval of its first combined phaco-vitrectomy system in December 2025 to formal commercialization today, Rhino Health has moved from "getting the certificate" to "monetizing." Completing two rounds of financing in 2026 means capital market recognition. In high-end ophthalmic surgical equipment, a field long dominated by European and American companies, Chinese companies have proven they can compete on the same stage.


Zhang Chi sees the current competition very clearly. "As more and more products obtain registration certificates and enter clinical use, the evaluation criteria will change accordingly." The next test is whether the company can keep iterating, serve global customers well, and gain a firm foothold in a broader market. Sustained technological leadership and closer-to-customer service are, in his eyes, the key to breaking through. Rhino Health will answer one by one with doctor training, growth in installations and overseas market expansion.